Originator
Progenics Pharmaceuticals
Developer
Albert Einstein Israelite Hospital; CytoDyn; Progenics Pharmaceuticals
Class
Antineoplastics; Antiretrovirals; Antivirals; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
Mechanism of Action
CCR5 receptor antagonists; Virus internalisation inhibitors

Orphan Drug Status
Yes - Graft-versus-host disease
New Molecular Entity
Yes
Available For Licensing
Yes - Non-alcoholic steatohepatitis

Highest Development Phases

Registered
Breast cancer
Preregistration
COVID 2019 infections; HIV infections
Phase III
COVID-19 pneumonia
Phase II
Graft-versus-host disease; Non-alcoholic steatohepatitis; Solid tumours
Preclinical
Autoimmune disorders; Stroke; Traumatic brain injuries
Discontinued
HIV-1 infections



10 Jan 2022
Pharmacodynamics data from a preclinical study in HIV-infection released by CytoDyn
10 Jan 2022
CytoDyn plans a clinical trial in Chronic fatigue syndrome
10 Jan 2022
Regnum, CytoDyn and SevenScore Pharmaceuticals enters into a assignment of the commercialization and license agreement and a related supply agreement to commercialize leronlimab in the US